Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Non-Current Deffered Revenue for 8 consecutive years, with $6.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue fell 72.41% year-over-year to $6.0 million; the TTM figure through May 2026 stood at $6.0 million (down 72.41% YoY), while the FY2025 annual figure was $10.0 million, down 61.8% from the prior year.
• Non-Current Deffered Revenue retreated to $6.0 million in Q2 2026 per NRIX's latest filing, from $7.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $55.4 million in Q1 2022 and bottomed at $6.0 million in Q2 2026.
• Historically, Non-Current Deffered Revenue has averaged $27.1 million across 5 years, with a median of $26.2 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue tumbled 75.35% — and 2024, when it jumped 191.5%.
• Nurix Therapeutics' Non-Current Deffered Revenue stood at $36.0 million in 2022, then climbed by 25.15% to $45.0 million in 2023, then sank by 41.79% to $26.2 million in 2024, then sank by 61.8% to $10.0 million in 2025, then plunged by 40.36% to $6.0 million in 2026.
• Business Quant data shows NRIX's Non-Current Deffered Revenue at $6.0 million in Q2 2026, $7.6 million in Q1 2026, and $10.0 million in Q4 2025.